Peculiarities of the endocrine status of women with precancerous lesions of the vulva
DOI:
https://doi.org/10.12775/JEHS.2024.60.56062Keywords
vulvar squamous intraepithelial neoplasia, high-grade intraepithelial neoplasia of the vulva, differentiated intraepithelial dysplasia of the vulva, Paget's disease of the vulva, in situ of the skin of the vulva, hormonal profile, thyroid status, insulin resistanceAbstract
The purpose of the study was to determine the hormonal profile of peripheral blood in women with precancerous lesions of the vulva.Material and methods. 309 women with precancerous lesions of the vulva and 60 gynecologically healthy women aged 25 to 70 years were included in the study. Patients with precancerous lesions were divided into 4 groups depending on the nosological unit: 87 women with severe vulvar dysplasia dependent on HPV (VHSIL), 154 individuals with differentiated vulvar dysplasia independent of HPV (dVIN), 36 patients with extramammary Paget's disease of the vulva (VPD) grade Ia and 32 women with melanoma in situ of the skin vulva In the groups with VHSIL, with dVIN, with melanoma in situ, there were women of premenopausal and postmenopausal age, therefore, for the comparison of hormonal data in these groups, subgroups were selected according to age: subgroups with persons younger than 50 years, subgroups of women aged 50 years and older. 60 conditionally healthy women of the control group also included 30 people under 50 years and 30 people 50 years and older. The levels of estradiol (E2), progesterone (P4), free testosterone (Tf), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), anti-Müllerian hormone (AMH), insulin, thyroid-stimulating hormone (TSH), free triiodothyronine (T3f), free thyroxine (T4f), antibodies to thyroperoxidase (ATPO)in blood serumand HOMA indexwere determined. The results. There was no difference between serum LH and FSH levels in women with various precancerous diseases of the vulva under the age of 50 years. Individuals with dVIN were characterized by the highest level of PRL (24.44±1.55 ng/ml). Among women aged 50 years and older, the highest levels of LH, FSH and PRL were observed in persons with melanoma in situ - respectively 36.90±2.09 mIU/ml, 74.67±4.06 mIU/ml, 9.85±2.03 ng/ml; the level of FSH and PRL was higher, and the LH/FSH ratio was lower than in controls in all precancerous diseases of the vulva. No statistically significant difference was found between the basal levels of serum P4 and AMH in subgroups of women younger than 50 years and 50 years and older. Among both premenopausal and postmenopausal women, the highest average levels of E2 were recorded in women with melanoma in situ (104.61±10.22 pg/ml and 30.71±1.90 pg/ml), Tf and Tf index - in patients with dVIN (3.20±0.10 pg/ml and 1.58±0.05 pg/ml vs. 8.25±0.24% and 3.77±0.10%, respectively). Features of the thyroid status were the highest indicators of TSH and ATP in persons with dVIN both in premenopause (2.68±0.30 mIU/ml and 196.39±76.48 IU/ml) and in postmenopause (2.23±0 .09 mIU/ml and 123.46±16.07 IU/ml). The average level of 25(OH)D did not differ statistically significantly between women with various precancerous diseases of the vulva. The level of insulin and NOMA index among premenopausal women was the highest in women with melanoma in situ (14.33±1.55 mIU/ml), in postmenopausal women with VPD (14.90±1.02 mIU/ml), HOMA index – respectively, with dVIN (2.87±0.30) and with VPD (3.60±0.27). Insulin resistance was most common in premenopause among individuals with dVIN (53.33%), and in postmenopause - with VPD (72.22%).Conclusions. Features of the hormonal profile of people with precancerous diseases of the vulva under the age of 50 are the highest levels of PRL, TSH and ATPO in women with dVIN, the highest average levels of Tf and Tf index, insulin level and HOMA index – in patients with VPD, the highest average levels of E2– in women with melanoma in situ. Among postmenopausal patients, the highest levels of TSH and ATPO in women with dVIN, the highest average levels of Tf and Tf index, the level of insulin and NOMA index in patients with VPD, the highest average levels of LH, FSH, PRL and E2 in women with melanoma are characteristic features situ. The average level of 25(OH)D does not differ statistically significantly between women with various precancerous diseases of the vulva. Insulin resistance is most common in premenopausal individuals with dVIN, and in postmenopausal individuals with VPD.
References
Wilkinson EJ, Kneale B, Lynch PJ. Report of the ISSVD terminology committee. J Reprod Med Obstet Gynecol. 1986;31:973-4.
Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med. 2005 Nov;50(11):807-10.
Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis. 2012 Jul;16(3):205-42. doi: 10.1097/LGT.0b013e31825c31dd.
World Health Organization, International classification of diseases for mortality and morbidity statistics (11th Revision), 2018. Available: https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/ 913387730.
Bornstein J, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl TG, et al. Terminology of Vulvar Squamous Intraepithelial Lesions. J Low Genit Tract Dis. 2016 Jan;20(1):11-4. doi: 10.1097/LGT.0000000000000169.
Crum C, Herrington C, McCluggage W. Tumours of the vulva; epithelial tumors. In: WHO classification of tumours of female reproductive organs. Lyon: IARC Press, 2014.
Schindler AE, Hormone replacement therapy (HRT) in women after genital cancer. Maturitas. 2002 April;41:105-111. https://doi,org/10.1016/S0378-5122(02)00018-X.
Sherman K,J, Daling J,R, McKnight B, Chu J. Hormonal factors in vulvar cancer: A case-control study. J Reprod Med Obstet, Gynecol. 1994;39:857-86. doi: 10.1016/0378-5122(95)91220-9.
Vieira - Baptista P, Lima-Silva J, Cavaco - Gomes J, Beires J, Martinez – de - Oliveira J. What differentiates symptomatic from asymptomatic women with lichen sclerosus? Gynecol Obstet Invest. 2015;79(4):263-8. doi: 10,1159/000367788.
Powell J, Wojnarowska F. Childhood vulvar lichen sclerosus: an increasingly common problem. J Am Acad Dermatol. 2001 May;44(5):803-6. doi: 10.1067/mjd,2001.113474.
Neill SM, Tatnall FM, Cox NH; British Association of Dermatologists, Guidelines for the management of lichen sclerosus. Br J Dermatol. 2002 Oct;147(4):640-9. doi: 10.1046/j.1365-2133.2002.05012.x.
Powell JJ, Wojnarowska F, Lichen sclerosus. Lancet. 1999 May 22;353(9166):1777-83. doi: 10.1016/s0140-6736(98)08228-2.
Vieira - Baptista P, Lima - Silva J, Cavaco - Gomes J, Beires J, Martinez-de-Oliveira J. What differentiates symptomatic from asymptomatic women with lichen sclerosus? Gynecol Obstet Invest. 2015;79(4):263-8. doi: 10.1159/000367788.
Goldstein AT, Marinoff SC, Christopher K, Srodon M. Prevalence of vulvar lichen sclerosus in a general gynecology practice. J Reprod Med. 2005 Jul;50(7):477-80.
Bleeker MC, Visser PJ, Overbeek LI, van Beurden M, Berkhof J. Lichen Sclerosus: Incidence and Risk of Vulvar Squamous Cell Carcinoma. Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1224-30. doi: 10.1158/1055-9965.EPI-16-0019.
Micheletti L, Preti M, Radici G, Boveri S, Di Pumpo O, Privitera SS, et al. Vulvar Lichen Sclerosus and Neoplastic Transformation: A Retrospective Study of 976 Cases. J Low Genit Tract Dis. 2016 Apr;20(2):180-3. doi: 10,1097/LGT,0000000000000186.
Lee A, Bradford J, Fischer G. Long-term Management of Adult Vulvar Lichen Sclerosus: A Prospective Cohort Study of 507 Women. JAMA Dermatol. 2015 Oct;151(10):1061-7. doi: 10.1001/jamadermatol.2015.0643.
Friedrich EG Jr, Kalra PS. Serum levels of sex hormones in vulvar lichen sclerosus, and the effect of topical testosterone. N Engl J Med. 1984 Feb 23;310(8):488-91. doi: 10.1056/NEJM198402233100803.
Clifton MM, Garner IB, Kohler S, Smoller BR. Immunohistochemical evaluation of androgen receptors in genital and extragenital lichen sclerosus: evidence for loss of androgen receptors in lesional epidermis. J Am Acad Dermatol. 1999 Jul;41(1):43-6. doi: 10.1016/s0190-9622(99)70404-4. Erratum in: J Am Acad Dermatol 2000 Jan;42(1 Pt 1):148.
Hodgins MB, Spike RC, Mackie RM, MacLean AB. An immunohistochemical study of androgen, oestrogen and progesterone receptors in the vulva and vagina. Br J Obstet Gynaecol. 1998 Feb;105(2):216-22. doi: 10.1111/j.1471-0528.1998.tb10056.x.
Carlson JA, Murphy M. Androgen receptors and lichen sclerosus. J Am Acad Dermatol. 2000 Sep;43(3):559-60. doi: 10.1067/mjd,2000.109276.
Günthert AR, Faber M, Knappe G, Hellriegel S, Emons G. Early onset vulvar Lichen Sclerosus in premenopausal women and oral contraceptives. Eur J ObstetGynecolReprod Biol. 2008 Mar;137(1):56-60. doi: 10.1016/j.ejogrb.2007.10.005.
Murphy R. Lichen sclerosus, Dermatol Clin. 2010 Oct;28(4):707-15. doi: 10.1016/j.det.2010.07.006.
Caruso G, Barcellini A, Mazzeo R, Gallo R, Vitale MG, Passarelli A, et al. Vulvar Paget's Disease: A Systematic Review of the MITO Rare Cancer Group, Cancers (Basel). 2023 Mar 16;15(6):1803. doi: 10.3390/cancers15061803.
Angelico G, Santoro A, Inzani F, Straccia P, Arciuolo D, Mulè A, et al. Hormonal Environment and HER2 Status in Extra-Mammary Paget's Disease (eMPD): A Systematic Literature Review and Meta-Analysis with Clinical Considerations. Diagnostics (Basel). 2020 Dec 3;10(12):1040. doi: 10.3390/diagnostics10121040.
Garganese G, Inzani F, Fragomeni SM, Mantovani G, Della Corte L, Piermattei A, et al. The Vulvar Immunohistochemical Panel (VIP) Project: Molecular Profiles of Vulvar Squamous Cell Carcinoma, Cancers (Basel). 2021 Dec 19;13(24):6373. doi: 10.3390/cancers13246373.
Chiavarini M, Naldini G, Giacchetta I, Fabiani R. Effect of Exogenous Hormones and Reproductive Factors in Female Melanoma: A Meta-Analysis [Letter].Clin Epidemiol. 2022 Feb 22;14:211-212. doi: 10.2147/CLEP.S356205.
Dika E, Patrizi A, Lambertini M, Manuelpillai N, Fiorentino M, Altimari A, et al. Estrogen Receptors and Melanoma: A Review. Cells. 2019 Nov 19;8(11):1463. doi: 10.3390/cells8111463.
Kemeny MM, Busch E, Stewart AK, Menck HR. Superior survival of young women with malignant melanoma. Am J Surg. 1998 Jun;175(6):437-44; discussion 444-5. doi: 10.1016/s0002-9610(98)00070-1.
Mervic L, Leiter U, Meier F, Eigentler T, Forschner A, Metzler G, et al. Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients. Melanoma Res. 2011 Jun;21(3):244-52. doi: 10.1097/CMR.0b013e32834577c8.
Donley GM, Liu WT, Pfeiffer RM, McDonald EC, Peters KO, Tucker MA, et al. Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States. Br J Cancer. 2019 Apr;120(7):754-760. doi:10.1038/s41416-019-0411-z.
Beral V, Evans S, Shaw H, Milton G. Oral contraceptive use and malignant melanoma in Australia. Br J Cancer. 1984 Nov;50(5):681-5. doi: 10.1038/bjc.1984.236.
Sun Q, Sun H, Cong L, Zheng Y, Wu N, Cong X. Effects of Exogenous Hormones and Reproductive Factors on Female Melanoma: A Meta-Analysis. Clin Epidemiol. 2020 Oct 29;12:1183-1203. doi: 10.2147/CLEP.S273566.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 V. Dunaevskaya
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 20
Number of citations: 0